核酸治療市場規模、佔有率和成長分析（按產品、適應症、最終用戶和地區）- 產業預測，2025-2032 年

全球核酸治療市場預計將在 2023 年達到 59 億美元，並從 2024 年的 67 億美元成長到 2032 年的 185.9 億美元，預測期內（2025-2032 年）的複合年成長率為 13.6%。

隨著人們對癌症、癲癇、糖尿病、結核病和愛滋病等慢性疾病的創新治療興趣日益濃厚，核酸治療市場可望快速成長。核酸，包括 DNA、RNA 和合成變體，對於向細胞傳遞基本訊息至關重要，並因其重要的治療應用而受到認可。隨著多種新治療方法的核准和強勁的開發平臺，市場正在蓬勃發展，這得益於製藥和醫療保健領域的進步，尤其是生物製藥和 DNA 療法領域的進步。隨著對有效慢性病治療的需求不斷成長，這為相關人員提供了充滿希望的機會，使基於核酸的解決方案處於現代醫學的前沿。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 宏觀經濟指標
• 價值鏈分析
• 定價分析
• 案例研究分析

核酸治療市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• 反義寡核苷酸 (ASO)
• RNA干擾（RNAi）
• RNA適體

核酸治療藥物市場規模（按適應症和複合年成長率） (2025-2032)

• 市場概況
• 自體免疫疾病
• 感染疾病
• 遺傳性疾病
• 癌症
• 其他

核酸治療市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院
• 診所
• 其他

核酸治療市場規模（依地區分類）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Wave Life Science Ltd.（Singapore）
• Imugene（Australia）
• Aileron Therapeutics Inc.（US）
• BioNTech SE（Germany）
• Protagonist Therapeutics Inc.（US）
• Replicate Bioscience Inc.（US）
• Eli Lilly and Company（US）
• Copernicus Therapeutics Inc.（US）
• Invio Pharmaceuticals Inc.（US）
• Benitec Biopharma（Australia）
• Alnylam Pharmaceuticals（US）
• Zydus Cadila（India）
• Excision BioTherapeutics（US）
• Pfizer Inc.（US）
• Rhythm Pharmaceuticals Inc.（US）
• Axcella Health Inc.（US）

結論和建議

Global Nucleic Acid Therapeutics Market size was valued at USD 5.9 billion in 2023 and is poised to grow from USD 6.7 billion in 2024 to USD 18.59 billion by 2032, growing at a CAGR of 13.6% during the forecast period (2025-2032).

The nucleic acid therapeutics market is poised for rapid growth, driven by increased interest in innovative treatments for chronic diseases, including cancer, epilepsy, diabetes, tuberculosis, and AIDS. Nucleic acids, encompassing DNA, RNA, and synthetic variants, are pivotal in conveying essential cellular information and are recognized for their critical therapeutic applications. With multiple new therapies gaining approval and a robust pipeline of developments, the market is experiencing an upswing, fueled by advancements in the pharmaceutical and healthcare sectors, particularly within biopharmaceuticals and DNA therapeutics. This landscape showcases a promising opportunity for stakeholders as the demand for effective chronic disease treatments continues to escalate, positioning nucleic acid-based solutions at the forefront of modern medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nucleic Acid Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nucleic Acid Therapeutics Market Segmental Analysis

Global Nucleic Acid Therapeutics Market is segmented by Product, Indication, End-user and region. Based on Product, the market is segmented into Anti-Sense Oligonucleotides (ASO), RNA Interference (RNAi) and RNA Aptamers. Based on Indication, the market is segmented into Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer and Others. Based on End-user, the market is segmented into Hospitals, Physicians' Offices and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is significantly driven by the rapid advancements in molecular technologies and the extensive research in the field of omics. This evolving landscape has prompted numerous companies to intensify their investments as they strive to enhance their competitive edge. As the market evolves, various business strategies, such as acquisitions, partnerships, and collaborations, play a crucial role in capturing market share and generating revenue. A notable example is Merck & Co.'s announcement in August 2022 regarding a collaborative effort with Orna Therapeutics aimed at discovering, developing, and commercializing innovative RNA-based therapies targeting vaccines, infectious diseases, and oncology.

Restraints in the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market faces significant restraints, notably in the area of delivery challenges. A primary obstacle is the effective transport of nucleic acid therapies to their intended target cells, as achieving precise localization while minimizing off-target effects is complex. The intricate nature of nucleic acid compounds often complicates their integration into existing biological systems, leading to potential inefficacies in treatment outcomes. As a result, overcoming these delivery-related issues is crucial for the market's growth, necessitating ongoing research and innovative solutions to enhance the precision and effectiveness of these therapeutic agents in clinical applications.

Market Trends of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is experiencing significant growth, fueled by heightened investments in healthcare services and a growing focus on advanced treatment methodologies. As the prevalence of genetic disorders and chronic illnesses rises, research and development efforts are intensifying, leading to innovative therapeutic solutions leveraging nucleic acids, such as RNA-based therapies and gene editing techniques. This surge in investment is not only accelerating the pace of research but also enhancing health facility capabilities, thereby expanding market opportunities. Additionally, increased collaboration between public and private sectors is facilitating breakthroughs in treatment, positioning nucleic acid therapeutics as a cornerstone in modern medical care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Nucleic Acid Therapeutics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Anti-Sense Oligonucleotides (ASO)
• RNA Interference (RNAi)
• RNA Aptamers

Global Nucleic Acid Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Autoimmune Disorders
• Infectious Diseases
• Genetic Disorders
• Cancer
• Others

Global Nucleic Acid Therapeutics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Physicians' Offices
• Others

Global Nucleic Acid Therapeutics Market Size & CAGR (2025-2032)

• North America (Product, Indication, End-user)
  • US
  • Canada
• Europe (Product, Indication, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Indication, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Wave Life Science Ltd. (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aileron Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protagonist Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Replicate Bioscience Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Copernicus Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invio Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Benitec Biopharma (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Excision BioTherapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axcella Health Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations